You are here

On Switching to dasatinib from imatinib

https://www.oncnet.com/news/early-switch-dasatinib-first-line-imatinib-m...

"Early Switch to Dasatinib From First-Line Imatinib May Benefit Patients With Ph+ CML"

Results reinforce the idea that if patients who start on imatinib do not quickly see optimal response switching early (i.e. don't stay on imatinib) to dasatinib can lead to significant clinical benefit.

I was an early beneficiary of these findings and was deliberately switched early from imatinib 400 mg to dasatinib (20 mg) when my response profile was mediocre at best and failed.

(Dr. Jorge Cortes was my doctor when he was at M.D. Anderson. He is now Director of the Georgia Cancer Center)

Thank you, Scuba, for this. I am not sure how an "early switch" is interpreted in the context of the article. I am nervously awaiting the results of my shift from imatinib to dasatinib.

According to the Professor Jane Applerley conference video 2019, in respect of imatinib 10% fail to response (primary resistance), 10% respond but then stop responding (secondary resistance), 30% plateau and 50% achieve a deep molecular response.

Resistance is defined as a failure to reach ELN guidelines.

About 50% of patients who are resistant will respond to a second generation TKI.

About 20% of patients who fail a second generation TKI will respond to a second second-generation TKI but about 50% will respond to ponatinib.

The referenced article in this posting appears to suggest a 64% chance of achieving an MMR within 24 months.